Navigation Links
Surveyed Physicians Report that Invokana Captures a Small Percentage of Patient Share in the Type 2 Diabetes Drug Market, With Significant Increases Expected Six Months from Now

EXTON, Pa., Oct. 31, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, among surveyed endocrinologists and primary care physicians (PCPs), Janssen Pharmaceuticals' Invokana captures a small percentage of type 2 diabetes patient share, with significant increases expected six months from now. Currently, a majority of type 2 diabetes patients are using metformin (excluding fixed-dose combinations) and one-third of patients are treated with long-acting insulins such as Sanofi's Lantus or Novo Nordisk's Levemir.


The TreatmentTrends®: Type 2 Diabetes (U.S.) 2013 report also finds that, within the GLP-1 drug class, Novo Nordisk's Victoza is the patient share leader, followed by Bristol-Myers Squibb/AstraZeneca's Byetta/Bydureon (if these products are considered independently).

The report examines five products in development for the treatment of type 2 diabetes—Bristol-Myers Squibb/AstraZeneca's dapagliflozin, GlaxoSmithKline's albiglutide, Eli Lilly's dulaglutide, Novo Nordisk's Tresiba and Takeda's fasiglifam. After reviewing a product profile, surveyed endocrinologists indicated a higher mean interest level for the long-acting insulin Tresiba versus the SGLT-2 inhibitor dapagliflozin.

"The report focuses on physician perception of type 2 diabetes product satisfaction, attribute importance, product performance and sales representative frequency and performance," said BioTrends Research Group Director Rob Dubman. "For example, the study found that at least 40 percent of surveyed physicians have seen a sales representative in the past month across 11 products in the survey; however, physicians were more likely to see Novo Nordisk's NovoLog and Merck's Januvia sales representatives in the past month, compared with representatives from Bristol-Myers Squibb/AstraZeneca's Byetta and Onglyza."

TreatmentTrends®: Type 2 Diabetes 2013 is a syndicated report, based on primary market research of 102 U.S. Endocrinologists and 55 U.S. PCPs, which provides a comprehensive view of the current and expected future management of type 2 diabetes patients, which published in October 2013. This report, which is new to the Decision Resources Group portfolio, includes a market overview, referral patterns, patient demographics, current and anticipated patient share, average lines of treatment, number of weeks on therapy, attribute importance and product performance, product satisfaction, sales representative frequency and performance, message recall, statement agreements, future treatment and desirable attributes for new type 2 diabetes treatments, among many other topics.

Members of the media are welcome to attend our upcoming webinar entitled Type 2 Diabetes in the United States—Clinical Practice in a Changing Market Landscape. This webinar will be held on November 19 at 10 a.m. U.S. Eastern Time. For more information, please contact Christopher Comfort at

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact: 

Decision Resources Group
Christopher Comfort

SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Surveyed U.S. Rheumatologists are Moderately Satisfied with Biologic Agents and Xeljanz to Treat Rheumatoid Arthritis
2. More than a Third of Chronic Kidney Disease-Non-Dialysis Patients are Likely Candidates for FG-4592/ASP1517, According to Surveyed EU5 Nephrologists
3. At One Month Post-Launch, Nearly a Quarter of Surveyed U.S. Oncologists Have Prescribed Tafinlar for Malignant Melanoma, Compared to 15 Percent Who Used Mekinist
4. Should Mircera Reach the U.S. Market, Surveyed Nephrologists State that at Least 40 Percent of CKD-ND and Dialysis Patients are Likely Candidates
5. According to Surveyed U.S. Oncologists, Zytiga is the Patient-Share Leader in First-Line Metastatic Castrate-Resistant Prostate Cancer
6. Surveyed U.S. Neurologists Report Greater Overall Satisfaction with Tecfidera than with Platform Injectables and Other Oral Multiple Sclerosis Therapies
7. At One Month Post-Launch, Nearly One-Quarter of Surveyed U.S. Medical Oncologists Have Prescribed Xofigo to Their Prostate Cancer Patients
8. A Significant Share of Surveyed Treatment-Naive and Prior Failure HCV Patients Plan to Initiate an HCV Treatment Regimen in the Next Year
9. Surveyed U.S. Neurologists Are More Likely Than Payers to Consider Biogen Idecs Tecfidera to be a Breakthrough in the Treatment of Multiple Sclerosis
10. Up to Sixty Percent of Surveyed U.S. Managed Care Organization Directors Expect to Cover Key Emerging Therapies for Parkinsons Disease on Their Largest Commercial Plan
11. The Majority of Surveyed Oncologists Prescribe Avastin Off-label to Their Ovarian Cancer Patients; However Approximately Half Encounter Access and Reimbursement Hurdles
Post Your Comments:
(Date:11/29/2015)... , Nov. 29, 2015 CIVCO Medical ... technology at the Radiological Society of ... Chicago November 29 – December ... designed to offer customers unrivaled versatility, enhanced user ... --> ...
(Date:11/27/2015)... -- --> --> ... potential to save costs, improve treatment quality and accelerate ... exploited as yet. Here, particular emphasis is placed on ... tablet or directly at the patients, bedside. ... -->      (Photo: ) ...
(Date:11/27/2015)... 2015 Research and Markets ( ) ... Devices Market 2015-2019" report to their offering. ... this report, the author the present scenario and growth ... To calculate the market size, the report considers revenue ... Hormonal IUDs and copper IUDs. The report forecasts the ...
Breaking Medicine Technology:
(Date:11/29/2015)... ... November 29, 2015 , ... ProStatic Analog Distortion ... tool designed specially for Final Cut Pro X. FCPX users can ... easy-to-use modification controls. Destoying and creating chaotic distortion is now quick and simple, ...
(Date:11/28/2015)... , ... November 28, 2015 , ... Safe storage for ... of two inventors, one from Lakewood, New Jersey and the other from Bradley Beach, ... patent-pending PROTECTOR to save the expense of having to replace NuvaRings more often than ...
(Date:11/27/2015)... Canada (PRWEB) , ... November 28, 2015 , ... There ... do we outperform our billings from last year? , This question has not been ... organizations are coming to the retirement age and the younger workforce don’t share the ...
(Date:11/27/2015)... ... November 27, 2015 , ... The rapid speed ... As people age, more care is needed, especially with Alzheimer’s, dementia and other ... are being overworked. The forgotten part of this equation: 80 percent of medical ...
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced ... offering customers 10% off of their purchase of lice treatment product. In addition, customers ... According to a company spokesperson. “Finding lice is a sure way to ruin the ...
Breaking Medicine News(10 mins):